FMA
AUPH icon

FNY Managed Accounts’s Aurinia Pharmaceuticals AUPH Stock Holding History

FNY Managed Accounts’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-750
Closed -$5K – 200
2017
Q1 		$5K Buy
+750
New +$3.46K 0.02% 616

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

FNY Managed Accounts's AUPH Position: Q2 2017 in Review

FNY Managed Accounts sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2017, closing a stake of 750 shares — an estimated $5K sold.

FNY Managed Accounts first reported a position in AUPH in Q1 2017 and held it in 1 quarter. The position peaked at $5K in Q1 2017. 65 funds tracked by Wall St. Rank hold AUPH as of Q2 2017.

  • FNY Managed Accounts reported no remaining Aurinia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 750 Aurinia Pharmaceuticals shares in Q2 2017, an estimated $5K.
  • FNY Managed Accounts first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Aurinia Pharmaceuticals position peaked at $5K in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.